April 21st 2024
During a Case-Based Roundtable® event, Raajit K. Rampal, MD, PhD, discussed the correlation between spleen volume responses and survival outcomes for patients with myelofibrosis in the second article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Observational Study Shows Mortality Rates, Causes of Death Within Polycythemia Vera Population
September 20th 2021In an interview with Targeted Oncology™ during the SOHO Annual Meeting, Carole Miller, MD, discussed results from the REVEAL study and how the findings can be used to aid future research.
Read More
Advances in the Polycythemia Vera Paradigm Signal Hope for Providers in Pennsylvania Cluster Area
August 13th 2021Above-average rates of polycythemia vera have been reported for over a decade due to causes unknown to experts. Intriguing new developments in the ongoing research of the genetic, toxicological, and environmental factors related to these cases have created reason to believe that this issue is not a thing of the past.
Read More
Phlebotomy Requirements Diminished With Rusfertide for Polycythemia Vera
June 15th 2021The hepcidin mimetic rusfertide is suggested to reduce the need for phlebotomy in patients with polycythemia vera, according to the results of the phase 2 PTG-300-04 trial presented during the European Hematology Association 2021 Virtual Congress.
Read More
Important Safety Data Evaluated in Meta-Analysis of Myelofibrosis
June 15th 2021Jan Philipp Bewersdorf, MD, discusses the safety outcomes of a systematic review and meta-analysis of 43 studies investigating efficacy and safety of allogeneic hematopoietic cell transplant in 8739 patients with primary or secondary myelofibrosis.
Watch
Cardiovascular Risk Management Requires Further Improvement for MPNs
June 14th 2021A proportion of patients with myeloproliferative neoplasms were not prescribed medications needed for the management of comorbidities in the United Kingdom, a poster presented during the 2021 European Hematology Association Virtual Congress showed.
Read More
Transfusion Independence at 24 Weeks Linked to Improved OS on Momelotinib in Myelofibrosis
June 11th 2021Subgroup analyses from the the phase 3 SIMPLIFY 1 and SIMPLIFY 2 trials show that achievement of transfusion independence by the 24th week of treatment is associated with an improvement in overall survival compared with continued transfusion dependence at that time point.
Read More
FDA Accepts NDA For Pacritinib to Treat Myelofibrosis and Thrombocytopenia
June 1st 2021The FDA has accepted and granted priority review to a new drug application for pacritinib for the treatment of patients with myelofibrosis and severe thrombocytopenia, defined as a platelet count less than 50x109/L.
Read More
BLA Resubmission for Ropeginterferon alfa-2b Accepted by FDA for Treatment of Patients with PV
May 21st 2021After receiving a complete response letter by the FDA, an approval application for ropeginterferon alfa-2b for treatment for patients with polycythemia vera. has been resubmitted to the FDA.
Read More